Aspira Womens Health is a diagnostics & research business based in the US. Aspira Womens Health shares (AWH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.76 – an increase of 6.67% over the previous week. Aspira Womens Health employs 64 staff and has a trailing 12-month revenue of around $8.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.76 |
|---|---|
| 52-week range | $0.67 - $5.65 |
| 50-day moving average | $0.84 |
| 200-day moving average | $2.06 |
| Wall St. target price | $4.25 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.42 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.7499 from 2024-11-25
| 1 week (2024-11-18) | 1.20% |
|---|---|
| 1 month (2024-10-25) | -22.29% |
| 3 months (2024-08-23) | -29.90% |
| 6 months (2024-05-24) | -67.25% |
| 1 year (2023-11-24) | -76.85% |
|---|---|
| 2 years (2022-11-25) | -85.72% |
| 3 years (2021-11-24) | 32.55 |
| 5 years (2019-11-25) | 11.2515 |
| Revenue TTM | $8.9 million |
|---|---|
| Gross profit TTM | $4.3 million |
| Return on assets TTM | -185.71% |
| Return on equity TTM | -723.45% |
| Profit margin | -178.8% |
| Book value | $-0.22 |
| Market Capitalization | $12 million |
TTM: trailing 12 months
We're not expecting Aspira Womens Health to pay a dividend over the next 12 months.
Aspira Womens Health's shares were split on a 1:15 basis on 11 May 2023 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aspira Womens Health shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Aspira Womens Health shares which in turn could have impacted Aspira Womens Health's share price.
Over the last 12 months, Aspira Womens Health's shares have ranged in value from as little as $0.6679 up to $5.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aspira Womens Health's is 1.438. This would suggest that Aspira Womens Health's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aspira Women's Health Inc. , together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.